Ignite Creation Date:
2025-12-25 @ 2:43 AM
Ignite Modification Date:
2026-02-03 @ 8:02 PM
Study NCT ID:
NCT02149433
Status:
COMPLETED
Last Update Posted:
2015-12-11
First Post:
2012-07-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pneumocystis Jerovici Pneumonia in Infants and Steroids
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D011014', 'term': 'Pneumonia'}], 'ancestors': [{'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D011241', 'term': 'Prednisone'}], 'ancestors': [{'id': 'D011244', 'term': 'Pregnadienediols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 78}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-05'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2015-12', 'completionDateStruct': {'date': '2015-02', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2015-12-09', 'studyFirstSubmitDate': '2012-07-09', 'studyFirstSubmitQcDate': '2014-05-28', 'lastUpdatePostDateStruct': {'date': '2015-12-11', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-05-29', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2014-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Reduction in inpatient mortality by 20%.', 'timeFrame': '36 months', 'description': 'To determine whether the addition of oral Prednisolone to standard treatment reduces inpatient mortality by 20% in patients aged 2-6 months with clinical PJP pneumonia.'}], 'secondaryOutcomes': [{'measure': 'Commencement of antiretroviral treatment', 'timeFrame': '36 months', 'description': 'To determine whether steroids significantly increase the number of patients that successfully commence anti-retroviral treatment.'}, {'measure': '6 month survival', 'timeFrame': '36 months', 'description': 'To determine whether steroids significantly increase the number of patients that survive to 6 months following commencement of anti-retrovirals.'}, {'measure': 'Morbidity (days in hospital and days on oxygen)', 'timeFrame': '36 months', 'description': 'To determine whether steroids significantly alter morbidity as determined by number of days spent in hospital as an inpatient and number of days on oxygen.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Pneumocystis Jiroveci', 'Steroids', 'Infants'], 'conditions': ['Pneumonia, Pneumocystis Jerovici']}, 'descriptionModule': {'briefSummary': 'This is a double-blind randomized controlled trial assessing the efficacy of adjuvant corticosteroids in clinically diagnosed Pneumocystis jiroveci pneumonia in infants.', 'detailedDescription': 'The study aims to determine whether the early administration of adjuvant corticosteroids in addition to high dose oral Co-trimoxazole reduces mortality amongst infants aged 2-6 months with vertically acquired HIV and clinically diagnosed Pneumocystis jiroveci pneumonia. Infants will be randomized to receive either a steroid regime of oral prednisolone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days or placebo.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '6 Months', 'minimumAge': '2 Months', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Consecutive infants with HIV and clinical features of Pneumocystis jiroveci pneumonia who require oxygen (oxygen saturations in air \\< 90%).\n* Clinical diagnosis of Pneumocystis jiroveci pneumonia will be made by one of the study investigators. All infants must be HIV ELISA positive or exposed, have an oxygen requirement (saturations on air \\< 90%) and have severe respiratory distress and cough. They may also have a low grade fever, clear chest or diffuse signs on auscultation and features suggestive of Pneumocystis jiroveci infection on chest radiography.\n\nExclusion Criteria:\n\n* Previous known allergy or hypersensitivity or other contraindication to corticosteroids or co-trimoxazole.\n* Previous treatment for suspected Pneumocystis jiroveci pneumonia or a delay starting steroids for greater than 24 hours after starting high dose co-trimoxazole.\n* Patients who are not exposed to HIV.\n* Infants with known preexisting active pulmonary or cardiac disease.\n* Patients who do not live within the Blantyre district and who are unable to attend follow up at QECH.\n* Infants whose parents or guardians refuse consent.'}, 'identificationModule': {'nctId': 'NCT02149433', 'briefTitle': 'Pneumocystis Jerovici Pneumonia in Infants and Steroids', 'organization': {'class': 'OTHER', 'fullName': 'Kamuzu University of Health Sciences'}, 'officialTitle': 'Early Steroid Use in Infants With Clinical Pneumocystis Jiroveci Pneumonia (PCP) in the Queen Elizabeth Central Hospital, Blantyre, Malawi', 'orgStudyIdInfo': {'id': 'Pneumocystis and Steroids'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Prednisone versus placebo', 'description': 'Prednisone 2mg/kg orally once a day x 7 days, 1 mg/kg orally once a day x 7 days and then 0.5 mg/kg orally once a day x 7 days', 'interventionNames': ['Drug: Prednisone', 'Drug: Placebo']}], 'interventions': [{'name': 'Prednisone', 'type': 'DRUG', 'description': 'The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.', 'armGroupLabels': ['Prednisone versus placebo']}, {'name': 'Placebo', 'type': 'DRUG', 'armGroupLabels': ['Prednisone versus placebo']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Blantyre', 'country': 'Malawi', 'facility': 'Queen Elizabeth Central Hospital', 'geoPoint': {'lat': -15.78499, 'lon': 35.00854}}], 'overallOfficials': [{'name': 'Laura Newberry, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Paediatric Department, College of Medicine, University of Malawi'}, {'name': 'Elizabeth Molyneux, FRCPCH', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Paediatric Department, College of Medicine, University of Malawi'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Kamuzu University of Health Sciences', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Lecturer Paediatrics and Professor', 'investigatorFullName': 'Elizabeth Molyneux', 'investigatorAffiliation': 'Kamuzu University of Health Sciences'}}}}